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   Optimised radiotherapy (RT) has opened 
unprecedented perspectives for improving 
the cure rate of cancer. A better under-
standing of the underlying physical 
and biological mechanisms along with 
exciting new technological developments 
make the specialty one of the most cha-
llenging disciplines in medicine. That is, 
if all the members of the multidisciplinary 
team involved in RT manage to stay 
on top of the developments and to steer 
the necessary changes. 
   The Board of ESTRO considers it as its 
priority Nr 1 to help and guide its members 
on this road. Without increased efforts 
in the field of Quality Assurance and 
Education the most promising technology 
turns into a needlessly complicated 
and potentially dangerous gimmick with 
no or even adverse effect on the outcome 
for the patient. 
   Fortunately, the Society can at any time 
count on the selfless commitment of its 
members who contribute substantial parts 
of their scarce free time to countless 
working parties to help ESTRO face up 
to this task. Robust support has also come 
from the European Commission in the way 
of funding for the most ambitious project 
ESTRO has ever undertaken: ESQUIRE. 
   Unfortunately, the optimism generated 
by the project was seriously tempered 
when the message was received that 
the” applicant states” of the EU would not 
be able to participate this time because 
no agreement had at that point been 
reached with them about the ratification 
of the EU treaty on Health and Consumer 
Protection, SANCO, the budgetary source 
of the project. Apart from some small 
concessions granted by the understanding 
and sympathising EC staff, there was no 
way for ESTRO to influence this political 
decision. But, if Central Europe misses out 
on the educational fellowships, the 4 tasks 
in the field of quality assurance will not 
benefit the total radiation oncology 
community. Below we give the aims of the 
project and the goals we hope to achieve 
in a 2 - year period. 
 
ESQUIRE: Education, Science and QUality 
Assurance In Radiotherapy in Europe 
 
   The outcome of radiotherapy (RT) 
is largely dose-dependant. The limiting 
factor in the therapeutic window 
of the dose delivered to the surrounding 
healthy tissues and organs at risk. 
Inaccurate dose delivery may result 
in serious side effects showing up as late 
as 15 years after the treatment. Under-
dosage boosts the risk of tumour 
recurrence. For this reason, the outcome 
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of RT (therapeutic ratio) cannot be based 
on the cure rate alone but needs to take 
into account the long term disease free 
survival of the patient. Strict quality assu-
rance procedures, including the monitoring 
of side effects need to be implemented 
as a precautionary measure. This will 
become even more mandatory with 
the introduction of conformal (CT) and in-
tensity modulated therapy (IMRT) that 
make dose escalation and hence the en-
hancement of the cancer cure rate possi-
ble. The aim of this project is to increase 
the confidence level of clinicians for em-
bracing optimised RT treatment regimes 
by making sure these can be achieved 
without an increase in severe side effects. 
Actions proposed for this purpose: mo-
nitoring the accuracy of the dose (Task 1: 
EQUAL) and the side effects (Task 2: 
REACT), stepping up education for the im-
plementation of new technology (Task 3: 
EDRO) by developing quality assurance 
procedures for optimised RT (Task 5: 
QUASIMODO) and brachytherapy (inter-
stitial and intracavitary treatment) (Task 6: 
BRAPHYQS), and establishing a proce-
dure-based surveillance of quality in treat-
ment and research (Task 4: EQART). 
 
   Task 1: EQUAL will try to include in its 
external mailed TLD dosimetric audit 
up to 80 % of all the RT departments 
in Europe, while developing a methodo-
logy for checking also more complex 
asymmetric and MLC (multileaf collimated) 
fields. 
 
   Task 2: REACT (Register, Educate 
and Ameliorate the Consequences of Tre-
atment) intends to involve patients 
in the assessment of consequences 
of treatment by developing a patient 
questionnaire. A consensus will be sought 
on levels of complexity for scoring them, 
and an education programme for their 
recognition and recording will be put 
in place. Finally methods will be developed 
for the management of side effects . 
 
   Task 3: EDRO (Education for Radio-
therapy), will focus on creating a European 
space for training and mobility in RT 
by the development/reviewing and promo-
tion of European curricula for the educa-
tion and practical training of all the disci-
plines involved in RT, by producing 
an easy-to-audit monitoring instrument 
for their professional training and develop-
ment including Continuing Medical Edu-
cation (CME): [the European Training 
Manual/ Record (TMR)], by stimulating 
the production and reproduction/publishing 
of cutting edge teaching material, by en-
couraging participation of trainees in state-
of-the-art educational activities, by facili-
tating the transfer of technology and know 
how and by creating a broadened recruit-
ment basis for research through research 
training fellowships.  
 
   Task 4: EPOQART (European Perma-
nent Office for Quality Assurance in RT) 
will serve as a co-ordinating structure 
for all the QA initiatives in the field of RT 
and develop a platform for the auditing 
and surveillance of Quality in the total 
Treatment Process and in Research in RT. 
 
   Task 5: QUASIMODO (Quality Assu-
rance for Intensity Modulated Radiation 
Oncology) will promote the safe intro-
duction of advanced technology in RT 
by developing procedures for the QA 
of Treatment Planning Systems (TPS) 
to be published as a new issue in a series 
of ESTRO Physics Booklets, and by explo-
ring a new methodology for the verification 
of Intensity Modulated Radiotherapy. 
 
   Task 6: BRAPHYQS will investigate 
methods for improving QA in Brachythe-
rapy (the use of radioactive implants 
as opposed to external beam radiothe-
rapy). QA procedures in different countries 
in Europe will be analysed and European 
guidelines published as a new issue 
in a series of ESTRO Physics booklets. 
A method for a mailed QC system will be 
developed for checking both dosimetric 
and geometric accuracy in brachytherapy 
departments.  
 
   Follow up: The progress in the different 
tasks will be followed up closely 
by the ESTRO Board and its relevant 
committees. 
 
   Methods: - development of guidelines, 
measuring tools and a physical infra-
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structure for carrying out the QA of im-
portant parameters in RT; - creating 
a European framework for education 
and training in radiotherapy and facilitating 
technology transfer and access to training 
for research. 
   The ESQUIRE project will give a sub-
stantial boost to ESTRO’s sustained effort 
for setting a benchmark for quality 
in the practice of radiotherapy in Europe. 
By developing the human potential 
through education and optimising the use 
of capital intensive infrastructure, the out-
come of radiotherapy treatment can be 
substantially improved. According to a re-
cently published EORTC study (Eur J Can-
cer 2000 Mar; 36 (5): 615-20, every gain 
in the accuracy of beam output and tre-
atment delivery will be directly translated 
into an important gain in uncomplicated 
cure probability and result in saving 
the lives of thousands of cancer patients 
every year. 50% of Europe’s cancer 
patients are treated with RT. It has been 
estimated by the Swedish Council of Te-
chnology Assessment that theoretically 
it would be possible to increase the 5-year 
survival of these patients by more than 
10% during a 10 year period if the radia-
tion treatment quality is improved. 
 
 
 
